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In early breast cancer axillary nodes are usually impalpable and over 50% of such patients may have an axillary clearance when
no nodes are involved. This work identiﬁes axillary node status by imaging with a Tc-99m radiolabelled anti-Polymorphic
Epithelial Mucin, humanised monoclonal antibody (human milk fat globule 1), prior to surgery in 30 patients. Change detection
analysis of image data with probability mapping is undertaken. A speciﬁcity of 93% and positive predictive value of 92% (both
100% if a second cancer in the axilla with negative nodes is considered) were found. A strategy for combining negative
imaging with the sentinel node procedure is presented.
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When breast cancer presents early or when it is demonstrated by
screening mammography, axillary nodes are often impalpable, so
their involvement or not with cancer cannot be identiﬁed clinically.
The need to determine axillary node status of patients with small
cancers of the breast is evident for staging, management and prog-
nosis. But over 50% of such patients have an ‘unnecessary’ axillary
clearance at surgery in that the axillary specimen shows no
involved nodes. The morbidity due to axillary clearance is acknowl-
edged.
Biassoni et al (1998) tackled the problem of identifying tumour
when axillary nodes were impalpable using Tc-99m SM3 monoclo-
nal antibody imaging with success. F-18 DG deoxyglucose, positron
emission tomography, PET, has also been used, but found unreli-
able in impalpable nodes (Wahl et al, 1991; Avril et al, 1996;
Bombardieri et al, 1996; Utech et al, 1996; Crippa et al, 1998).
The sentinel node approach is becoming the established technique
for predicting axillary node status (Veronesi et al, 1997; Krag et al,
1998; Schlag and Veronesi, 2000). However the event is per-opera-
tive. The colloid used is not speciﬁc for cancer, only for identifying
the node or nodes. Their excision has to be combined with histol-
ogy. Imaging to determine axillary node status prior to surgery
would allow the patient and the surgeon in principle to be
prepared for axillary clearance as well as wide excision of the breast
tumour or else wide excision alone. This study progresses the work
of Biassoni et al (1998) by using a Tc-99m radiolabelled anti-Poly-
morphic Epithelial Mucin (PEM) humanised monoclonal antibody
(human milk fat globule 1), hHMFG1. A simple strategy for
combining this imaging with the current sentinel node approach
is presented.
MATERIALS AND METHODS
Preparation of humanised hHMFG1 monoclonal antibody
Verhoeyen et al (1993) developed the anti-Polymorphic
Epithelial Mucin, PEM, humanised monoclonal antibody
(human milk fat globule 1), hHMFG1 by genetic engineering
(Jones et al, 1986; Riechmann et al, 1988; Gorman et al,
1991). The master cell culture was shown to be virus free
when used for the production of hHMFG1. This was puriﬁed
by epitope afﬁnity chromatography and immunoreactivity
checked using puriﬁed milk mucin and fast protein liquid
chromatography. Protein electrophoresis of the puriﬁed
samples of the hHMFG1 antibody conﬁrmed the presence of
the heavy and light chains. The immunoreactivity of the
humanised HMFG1 was found to be similar to the murine
of over 90%. The relative afﬁnities of the two antibodies were
shown to be almost identical.
Epitope mapping was undertaken using the known epitope
sequence synthesised as a series of amino acid sequences with the
central PDTRP amino acid sequence. Removal of any one of the
P, D, T or R led to loss of the binding capacity of either the human
or the murine antibody indicating their speciﬁcity for the same
epitope. From this data Verhoeyen et al (1993) concluded that
the murine and the human reshaped HMFG1 are similar if not
identical in their ﬁne speciﬁcity and relative afﬁnities for epithelial
mucins. The preparation is aliquotted into vials in 1 mg amounts
and transferred to the Nuclear Medicine Research Laboratory at
St Bartholomew’s Hospital. These are deep frozen at 7808C and
used as required.
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Photoreduction of the antibody was performed using a standard
laboratory transilluminator (UVP Inc, San Gabriel, CA, USA)
containing two 300 nM UV tubes. Five ml of 50 mM PBS pH 7.0
containing 0.5 mM ethylenediaminetetraacetic acid (EDTA) was
injected into a 10 ml nitrogen-ﬁlled borosilicate glass vial with a
rubber septum and the solution was purged with nitrogen for
15 min. Five hundred ml of 5 mg ml
71 hHMFG1 antibody in
PBS was injected into another 10 ml vial and the vial was purged
with nitrogen for 15 min. An Amerscan Medronate II kit contain-
ing 5 mg sodium medronate, 0.34 mg stannous ﬂuoride and 2 mg
sodium p-aminobenzoate (Nycomed Amersham, Amersham, UK)
was reconstituted with 2.0 ml of the nitrogen-purged PBS/EDTA.
Two hundred ml of this medronate solution was injected into the
vial containing the antibody and the vial was irradiated for
40 min 2 cm away from the exposed UV tubes of the transillumi-
nator. The irradiated antibody was then divided into 500 mg
aliquots in nitrogen-purged 2 ml vials and frozen at –408C until
required.
Photoreduced antibody prepared using this procedure was radi-
olabelled by addition to 500 mg of antibody of 740 MBq of sodium
[99m-Tc] pertechnetate eluted from a 99-Mo/99m-Tc radionuclide
generator (Nycomed Amersham, Amersham, UK) and incubation
at room temperature for 30 min. Radiochemical purity of the
labelled preparations was measured by HPLC and ITLC methods
as previously described (Stalteri and Mather, 1996) and in all
instances exceeded 95%. Immunoreactivity of the photoreduced
antibody was compared with the native antibody using a solid-
phase ELISA assay on plates coated with a GST-MUC1 fusion
protein (Apostolopoulos et al, 1993; Wilkinson et al, 2000). No
signiﬁcant differences were seen between the binding of the
reduced and control antibody preparations.
Patients
All the patients were referred from the surgical breast clinic, mostly
from the breast screening programme. The breast clinic is run
twice weekly at St Bartholomew’s Hospital. It is a ‘One stop’ clinic,
where radiology and cytology are available directly after the patient
has been seen. In this clinic a full medical history is taken with
emphasis on the breast problem and any family history of breast
cancer, followed by a careful examination of breasts. Both axillae
and supraclavicular regions are examined for any palpable nodes
and the ﬁndings are recorded.
The patient then has mammography of both breasts. Ultrasound
is routinely done for the breasts and to the liver. All the patients
have a ﬁne needle aspiration to examine the cytology of the breast
lump at the time of their attendance or afterwards. Some of these
patients have to have a core needle biopsy to conﬁrm the suspicion
of non-diagnostic ﬁne needle aspiration or non-diagnostic radiolo-
gical ﬁndings.
Once the treatment options have been explained, the patient has
the radiolabelled monoclonal antibody imaging explained and
informed signed consent is obtained. The patient is asked about
any allergies to inoculations. If positive the patient would be
excluded from the test but no such patient was found so none were
excluded. The breast surgery is usually undertaken within a month
of the histological diagnosis and the imaging with Tc-99m
hHMFG1 within 2 weeks before surgery.
Preparation of the patient for imaging
The patient is asked to wear the same bra for each study. The
activity to be injected is checked. Six Cobalt-57 markers are placed
over bony and other landmarks, previously marked with an indel-
ible marker. These are the reference points for next day imaging.
The Co-57 landmarks are positioned on the suprasternal notch,
bilateral mid-clavicular line, xiphisternum, the nipple of the
diseased breast and the tumour site. In case of right breast tumour,
a ﬂexicurve lead is used to outline the breast to identify it sepa-
rately from the liver. For the left breast no ﬂexicurve is used.
The usual activity is 600 MBq of Technetium-99m labelled to
0.5 mg hHMFG1, which is injected intravenously when the patient
is lying down supine on the camera couch. In the case of bilateral
breast tumours the injection is given in the arm opposite to the
side of the planned axillary clearance. The patient is positioned
supine with the arms at right angles to the body on armrests.
The camera is positioned anteriorly over the chest. By the help
of a transparent X-ray ﬁlm attached to the computer screen, the
six markers are marked on the ﬁlm, using a permanent ink pen.
This transparent ﬁlm is used as a reference for imaging the
patient at 3 h and 24 h. The transparent ﬁlm is cut to the size
of the computer screen and ﬁxed on the surface of the screen using
tape. All six markers are marked on the ﬁlm specifying the tumour
and the nipple sites. Then the images are acquired. Two sets of
static anterior chest images are obtained on the ﬁrst day: 10 min
post injection and at about 3 h post injection. A further image is
obtained the next day at about 24 h. The Orbiter gamma camera
(Siemens, Erlangen) linked to Hermes computer system (Nuclear
Diagnostics, Stockholm) is used. The gamma camera is peaked
on an energy level of 140 KeV, window 15%, set with a matrix size
of 2566256 and with a general purpose high resolution collimator.
Ten minutes post injection, the six markers’ view is acquired for
30 s. Then 1000 K counts are acquired for an image of the anterior
chest with the view including both breasts and axillae extending
from the cricoid cartilage to costal margins. The image data is
transferred to the computer system. Three to 4 h and 18–24 h
post injection, the procedure is repeated. The planar images are
reviewed and the image data undergoes Change Detection Analysis,
CDA.
Interpretation of images
The planar images are reviewed. The change detection analyses are
presented as probability maps of the signiﬁcances of the differences
of the images at pairs of time points. These are colour coded: Red
is P50.001; Yellow, P50.01; Green, P50.05; Blue; P50.05, Dark
blue or Black, P40.1 for the signiﬁcance of the differences.
P50.05 is taken as the divide between a positive and a negative
detection of axillary node involvement. Findings of the probability
mapping were evaluated to take into account other areas with
increase of uptake. These may be due to imperfect registration or
repositioning of the patient during the 22 h image. Areas above
the brachial and subclavian arteries where there was with CDA
an increase with time of radiolabelled antibody were considered
not relevant, because of frequent artefacts due to neck movements.
Small cancers do not usually spread above the clavicle.
As the liver is the organ where antibodies are metabolised, there
was always an increase of activity with time, so the organ was
isolated in a region of interest and excluded. Areas of negative
change including the heart and big vessels were also isolated in
region of interests and excluded.
For hHMFG1 imaging, the planar images are called negative or
positive on visual inspection of the black and white images prior to
knowledge of the CDA ﬁndings. The outcome of Tc-99m hHMFG1
imaging of the axilla is reported as TP true positive, FN false nega-
tive, TN true negative and FP false positive in relation to the
histological ﬁndings.
Specimen handling
The Pathology Department receives the pathology form on which
the patient data and clinical ﬁndings are recorded, together with
labelled specimens. The written record of the activity counts is
also provided. All specimens are placed on the tray designated
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the specimens by using a Geiger–Muller counter, recording the
counts of each specimen separately. The pathologist dissects
and separates the lymph nodes from the axillary clearance speci-
mens. The pathologist also separates the sentinel node from its
bed when that technique has been performed, and dissects the
primary tumour. The specimens are stored in formalin solution
in separate containers and kept in a lead box in the pathology
laboratory until ready for processing. The nodes have multiple
sections depending on their size. If nodes are macroscopically
positive then one section only is taken, otherwise nodes greater
than 5 mm have multiple sections, those less than 5 mm are
embedded in their entity. The breast tumour is examined routi-
nely. Haematoxylin and eosin staining is performed for each of
the sections taken from each block. Immunocytochemistry is
not used routinely. The grading is performed by the Elston
and Ellis method, dividing tumours into grade 1, 2 and 3, as
well as a short description of the type of breast cancer e.g. inva-
sive ductal carcinoma. DCIS is ductal carcinoma in situ that is
conﬁned within the ductal system.
Change detection analysis, CDA, with probability mapping
Lymph nodes are small, sometimes deep and malignant cells show
relatively low antibody uptake, of the order of 0.01% injected dose
per gram. This makes it difﬁcult for conventional visual interpreta-
tion of planar images to be reliable and to conﬁrm such nodes as
being clinically involved. The detection of an involved lymph node
is essentially that of detecting a faint radioactive signal in a back-
ground of radioactive noise. For such lesions a tumour to noise
ratio or contrast, ct, can be deﬁned as:
ct  Rt ÿ Rb=Rt  Rb
Where Rt is the counting rate recorded over the lesion and Rb is
the counting rate recorded adjacent to it (Sorenson and Phelps,
1987).
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Table 1 Ic-99m-hHMFG1 imaging results
No Initials Age Site Size Hx report Planar Br. CDA Br. Hx Sn Hx Ax Planar Ax. CDA Ax. Result
1 BC 57 Right 25 GIII Invasive ductal carcinoma Negative Positive 0/1 3/13 Negative Positive TP
2 BJ 66 Left 17 GII mixed lobular and ductal Positive Negative 1/1 2/29 Negative Negative FN
3 BA 55 Left 16 GII Inﬁltrating ductal carcinoma Positive Positive 1/2 0/13 Negative Negative FN
4 CP 46 Left 15 GIII Invasive ductal carcinoma Positive Positive 0/1 2/19 Negative Positive TP
5 CT 46 Left 30 GIII ductal carcinoma Positive Positive 0/1 0/16 Negative Negative TN
6 EAL 65 Left 19 GII Invasive ductal carcinoma Negative Positive 0/2 0/10 Negative Negative TN
7 EAR 65 Right 21 GII Invasive lobular carcinoma Positive Positive 2/2 6/14 Negative Negative FN
8 HM 55 Left 13 Ductal carcinoma Negative Positive 1/1 2/16 Negative Positive TP
9 HSL 56 Left 37 Ductal carcinoma in situ Negative Positive 0/2 0/12 Negative Negative TN
10 HSR 56 Right 31 Micro-papillary DCIS Negative Positive 0/1 0/12 Negative Negative TN
11 HB 70 Left 15 GIII Invasive ductal carcinoma Negative Negative 0/1 0/9 Negative Negative TN
12 H Pat 60 Right 12 GII Invasive ductal carcinoma Positive Negative 0/2 0/18 Negative Negative TN
13 H Paul 40 Left 10 GII ductal carcinoma in situ Negative Positive 1/2 1/18 Negative Negative FN
14 MJ 51 Left 50 Poorly differentiated ductal Positive Positive 1/1 2/4 Positive Positive TP
15 OJ 80 Right 17 GI Invasive lobular carcinoma Negative Positive 1/1 10/17 Negative Positive TP
16 RS 55 Left 17 GIII Inﬁltrative ductal carcinoma Positive Positive 3/3 19/29 Negative Positive TP
17 VN 74 Right 30 Inﬁltrating ductal carcinoma Negative Positive 0/1 2/10 Negative Negative FN
18 WM 66 Right 26 GII Invasive micropapillary Positive Positive 0/1 1/14 Negative Positive TP
19 BL 43 Right 30 GII mixed ductal and lobular Negative Positive – 7/18 Negative Negative FN
20 D Mau 40 Right 40 Lobular carcinoma Positive Positive – 0/16 Negative Positive FP
21 D Mar 60 Left 15 GIII Ductal carcinoma Positive Positive – 0/11 Negative Negative TN
22 GM 74 Right 25 GII mixed ductal and lobular Positive Positive – 2/6 Negative Positive TP
23 GD 52 Right 16 GI Invasive mixed lobular and ductal Positive Positive – 0/17 Negative Negative TN
24 HH 54 Right 48 GIII inﬁltrative ductal carcinoma Positive Positive – 2/21 Negative Positive TP
25 HE 51 Left 12 CIII inﬁltrative ductal carcinoma Positive Positive – 3/13 Positive Positive TP
26 PK 49 Left 15 GIII invasive ductal carcinoma Positive Positive – 0/12 Negative Negative TN
27 PT 51 Left 20 GII invasive ductal carcinoma Negative Positive – 1/13 Negative Positive TP
28 SB 52 Right 49 GIII invasive ductal carcinoma Positive Positive – 11/17 Negative Negative FN
29 SL 53 Right 27 GII inﬁltrative ductal carcinoma Negative Positive – 0/13 Negative Negative TN
30 SK 53 Left 12 GIII ductal carcinoma in situ Positive Positive – 0/2 Negative Negative TN
31 WD 70 Left 30 Inﬂtrative ductal carcinoma Positive Negative – 0/18 Negative Negative TN
32 WE 75 Right 15 GII Micro-papillary carcinoma Positive Positive – 0/15 Negative Negative TN
Ax. Pal=Axillary node palpable. Hx=Histology graded GI-GIII. Br=Breast. Sn=Sentinel node. Ax=Axillary. R=Report. CDA=Change Detection Analysis. TN=True Negative.
FN=False Negative TP=True Positive. FP=False Positive. –=Not present (Axilla) or not done (Sn study). +=Present.
Table 2 Radioimmunoscintigraphy with Tc-99m hHMFG1
Planar imaging of breast cancer
True positive 20 Sensitivity 62.75%
False negative 12
Change detection analysis of breast cancer
True positive 28 Sensitivity 87.5%
False negative 4
Planar imaging of the axilla
True positive 2 Sensitivity 10.5%
False negative 17 Speciﬁcity 100%
True negative 13 Accuracy 47%
False positive 0 PPV 100%
Total 32 NPV 43%
Change detection analysis in axillary nodes
True positive 11 Sensitivity 61%
False negative 7 Speciﬁcity 93%*
True negative 13 Accuracy 75%
False positive 1 PPV 92%*
Total 32 NPV 65%
*100% if second cancer with negative nodes is considered.
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Taking the background to exhibit a uniform counting rate of Ro,
which is then added to the image, then the tumour contrast ratio
is now given by:
ct f  Rt  Roÿ Rb  Rog=fRt  Ro Rb  Rog
 Rt ÿ Rb=Rt  Rb  2Ro
From this expression it may be seen that the tumour contrast ratio
is reduced by the additional factor 2Ro in the denominator.
Observer studies have shown that the minimum tumour
contrast ratio for tumour sites to be detected reliably by the human
visual system, usually using transparent ﬁlm, is at least ﬁve.
As the tumour to background ratio is usually low and as scatter-
ing and attenuation of photons within the patient is another
problem, so statistical probability mapping, SPM, with a change
detection algorithm has been investigated to see if it provides an
acceptable solution.
The process of SPM is that of deriving a parametric image
whose elements contain the signiﬁcance P-value returned from
performing some parametric or non-parametric statistical test
between the pixels of the two images being compared. There
may be considered to be two distinct approaches to SPM compris-
ing: Global linear regression and pixel by pixel statistical
comparison.
Global linear regression utilises a two-dimensional co-occur-
rence matrix or scatter graph. This matrix may for example
have dimensions 2566256, where the matrix size determines
the maximum count that can be processed in the images being
compared. Each pixel count in the two images A and B being
compared is used to index into the co-occurrence matrix where
the pixel counts in image A is used as a column index and the
respective pixel counts in image B provide the row index. Each
such location in the co-occurrence matrix is incremented by
one hence the result after processing all the pixel counts in
images A and B is that of a two dimensional histogram
describing the joint pixel count distribution between the two
images. If the images are identical the results fall on the line
of identity. Deviations from this line can be tested for signiﬁ-
cance using a Chi square test. A Cluster requirement can
then be applied so that, for example, ﬁve pixels with signiﬁcant
deviations must be adjacent to be judged signiﬁcant. This
avoids single outlier pixel values. The probability map is then
constructed.
The two dimensional co-occurrence matrix approach is a rela-
tively simple approach to statistical change detection providing a
straightforward statistical signiﬁcance and sense i.e. positive or
negative areas of change between successive homologous images.
This approach has been used successfully in ovarian cancer (Gran-
owska et al, 1988) but suffers from some potentially serious
disadvantages.
These are ﬁrstly the assumption of a linear relationship between
the counts in the two images being processed. This assumption
may be violated by variations in gamma camera response between
data acquisitions taken 24 h apart. Secondly and more serious is
that large areas of very positive change, for example the liver in
immunoscintigraphy, will dominate in calculating the regression
line thus swamping the contributions from small areas of positive
change with far fewer pixels.
Because of these limiting factors the second approach to SPM
was investigated called Statistical Pixel by Pixel Comparison.
Localised pixel comparisons between images was used as the
method of choice for the detection of axillary lymph node involve-
ment, because of the disadvantages of global linear regression
mentioned above. Prior to statistical pixel comparison an image
normalisation or pre-whitening stage is carried out. Besides aiding
in the detection process directly this image normalisation process
has a second important consequence. When performing a statistical
test upon a set of data then the power of any such test is directly
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Figure 1 Patient CP 4, Tc-99m hHMFG-1 radioimmunoscintigraphy. Positive left axillary nodes and breast cancer.
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within the data set. But in the case of image data such indepen-
dence assumptions are seen not to hold by virtue of each pixel
being highly correlated with its neighbours. This interpixel correla-
tion is a consequence of the imaging equipment’s ﬁnite point
spread function or resolution at the short scale, and, at larger scales
from sampling common large underlying structures such as the
liver in immunoscintigraphy. The image normalisation process
ensures a signiﬁcant pixel to pixel decorrelating effect and therefore
the independence requirement of a chosen statistical test is largely
met. This normalisation process takes the form of a transformation
described by the expression:
Jx;yrsfIx;yÿmix;y=ri x;yg  ms:
Where (mi) and (i) are the local mean and standard deviation of
the input image, (I), measured over a local (n6n) window
centred at the current pixel position x,y and where (ms) and
(rs) are the required mean and standard deviation of the output
image (J).
This mapping is called statistical scaling and is related to the
image processing technique of unsharp masking. A window, 565
pixels in extent has been chosen for the current application. For
the two homologous images, a small-centralised window or group
of pixels is extracted for each pixel, using the window size of 565
pixels square. For each of these small sub-populations a parametric
or nonparametric test statistic may be calculated for some property
associated with the image pixels. This property is usually the radio-
active counts per pixel but it is important to stress that any derived
quantity from the images may be used as a valid input, for example
measures of surface shape or texture. The chosen parametric statis-
tical test for this application is that of the paired t-test where the
signiﬁcance of any difference in the mean counts of the windowed
pixel subset is tested.
The null hypothesis that a signiﬁcant difference or a tumour is
not present (H0) is rejected when for (na+nb-2) degrees of free-
dom of the t distribution, the level of signiﬁcance, P-value,
returned by the test is greater than a prescribed level of signiﬁcance
e.g., a P-value 40.05.
With a 565 window size, na, nb=25 and where a and b are the
means of the sample values, there are 25 + 25 72=48 degrees of
freedom. Referring to statistical tables of the t distribution, a value
of ‘t’ greater or equal to 2.42 would indicate a P-value of 0.005, a
highly signiﬁcant result and the null hypothesis (H0) would be
rejected. Various P-values are presented by mapping to some
chosen colour table. For this application P50.001 is plotted in
red, P50.01 in orange, P50.05 in green, P50.05 in blue and
P40.1 in dark blue or black.
In summary, the process of generating the SPM parametric
image is image registration, change detection and image output
as a probability map.
Results of breast and axillary imaging
The 32 patient’s ages ranged from 40–80 years old, mean 57.3
years, SD 10.7 years. The breast tumours ranged from 10–
50 mm diameter with a mean of 23.6 mm, standard deviation
11.3 mm. There were 17 patients with cancer in the left breast
and 15 in the right breast. The positions of the tumours were
mainly upper outer quadrant of the breast, 22; upper inner quad-
rant, three; lower outer quadrant, six; lower inner quadrant, none;
and one central tumour. The patient data and the correlation with
histology are shown in Table 1. Of the total of 478 lymph nodes
sampled in these 32 women, 87 showed histological involvement
with breast cancer. A subset of 26 sentinel nodes in their axillae
showed involvement in 11, Table 1. Both true positive and false
negative images were found when only one or two out of many
axillary nodes were involved, Table 1. The results in Table 2 show
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Figure 2 Patient BC 1, Tc-99m hHMFG-1 radioimmunoscintigraphy. Positive right axillary nodes and breast cancer.
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Representative images are shown in Figures 1–4.
The pharmacokinetics of Tc-99m hHMFG1 were investigated.
The T1/2 slow component was approximately 26 h. The 24 h urine
output of Tc-99m labelled metabolic products, usually Tc-99m
dicysteine, was approximately 50% of the injected activity.
DISCUSSION
Radioimmunoscintigraphy of breast cancer started in this
department with murine monoclonal antibody 19 years ago
(Epenetos et al, 1982). The aim of this study was to detect
malignant involvement in impalpable axillary lymph nodes prior
to surgery in women with proven breast cancer by imaging
with a technetium-99m radiolabelled ‘humanised’ monoclonal
antibody.
Axillary clearance, although associated with some morbidity, is
considered an essential and standard part of an operation to
remove breast cancer in order to stage the disease. Nodal status
determines prognosis and the choice of therapy. However, up to
50% of these women with breast cancer over 1 cm diameter have
an ‘unnecessary’ axillary clearance in that the nodes are shown
histologically to be free of cancer. The reliable determination by
imaging of involvement or not of impalpable axillary nodes in
the days prior to surgery would allow the surgeon to tailor the
extent of the operation to the individual woman, who would be
forewarned. A positive image would indicate the need for this
clearance and a normal image would indicate no need. However,
it is difﬁcult to prove the absence of a micrometastasis when an
image of the axilla is negative. A strategy, in which there is the
addition of the Sentinel node technique per-operatively, is intended
to conﬁrm a negative as true and thus conﬁrm that axillary clear-
ance would not be necessary.
Radiological techniques, X-ray CT, MRI and or ultrasound have
a ‘normal’ cut off limit of 1 or even 1.5 cm diameter. Thus a node
less than 1 cm diameter, which is detected by these techniques, has
to be considered normal or else these techniques would have an
unacceptable high false positive rate for cancer detection in lymph
nodes. Yet it is clear that for a cancer to enlarge a node to over
1 cm diameter, it must have been present in a normal size node.
The success of radioimmunoscintigraphy in identifying small
cancers, local involvement of normal sized lymph nodes and recur-
rent cancers that spread in sheets or ribbons or recur as plaques, is
that the technique is essentially one of identiﬁcation or character-
isation of a tissue type. It is making use of the subtle differences
between the cancer cell and the normal cell. A radioactive pinhead
is identiﬁable if it has enough radioactivity on it, although it may
appear over a centimetre across on the gamma camera image
because of that imaging system’s inherently poor resolution. It is
the number of molecules that contain a radioactive signal that bind
to each cancer cell that is the crucial determinant. Where tumour
associated antigens are concerned there are between 5000 and
50000 accessible antigens per cell. It has been calculated that there
are up to 10000 HMFG1 epitopes accessible for binding on a typi-
cal malignant breast cancer cell surface. This in principle gives a
considerable ampliﬁcation factor, which helps to overcome the
poor photon yield of radiopharmaceuticals with gamma camera
imaging. The order of magnitude greater detection sensitivity over
single photon agents of PET equipment for Positron Emitting F-18
of FDG helps to account for its success. However the ampliﬁcation
of the Glucose Transporter protein 1 because of its upregulation in
malignancy as compared to normal tissue appears to be only ﬁve to
10-fold.
The polymorphic epithelial mucin, PEM, antigens are epithelial
antigens hidden from the blood stream in normal tissues such as
the lining of the lactiferous duct in the breast or the internal
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Figure 3 Patient CT 5, Tc-99m hHMFG-1 radioimmunoscintigraphy. Negative left axilla nodes and positive breast cancer.
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disorganisation of the malignant process that exposes such antigens
to the blood stream as well as their up regulation that allows
cancer detection by monoclonal antibodies such as HMFG1 either
immunohistochemically or by radioimmunoscintigraphy.
The detection system has to be optimised to obtain the best
images. There is a further consideration. The time dependency of
biological processes is one of nuclear medicine’s greatest strengths
(Britton and Granowska, 1987). This time dependency of monoclo-
nal antibody uptake by cancer is the key to the further speciﬁcity of
radioimmunoscintigraphy for detection of small lesions. Speciﬁc
uptake increases with time. Thus an image at 5–10 min at which
time there is virtually no uptake of the monoclonal antibody by the
cancer, acts as a template with which to compare the later images.
This is the basis of the change detection analysis, CDA, also called
statistical probability mapping, SPM, which latter has been used for
functional MRI of the brain, reviewed by Acton and Friston (1998).
In contrast non-speciﬁc uptake after the initial distribution
decreases with time as the agent diffuses out of the lesion as the
blood level of the antibody falls with time.
To undertake CDA involves correct registration of the images.
This is ﬁrstly by setting the patient in the same position for each
view as far as possible by the use of the markers and the transpar-
ent ﬁlm procedure. Secondly by the computer’s translation rotation
program. Superimposable images are a requirement for the change
detection analysis program to be applied. This tests the signiﬁcance
of the difference between the two images, the early and late. This
signiﬁcance is plotted as a colour coded probability map. The
sophisticated version of CDA used here followed the earlier simpler
approach, published ﬁrst in the context of ovarian cancer by Gran-
owska et al (1988), and the more recent reﬁned technique applied
to the imaging of the axillary nodes in breast cancer using Tc-99m
SM3 (Biassoni et al, 1998). It has been further reﬁned using the 25
cell matrix whose central pixel is applied successively to each pixel
of each image. This approach allows for some slight movement and
distortion between the two images and gives a robust probability
map.
The CDA has a number of problems. The registration is crucial.
Alignment of the patient using the markers and transparent ﬁlm is
the ﬁrst step, but it does not allow for twisting of the patient’s
body. For this reason, although theoretically only three markers
are needed to deﬁne co-registration, six markers are used. The
two for the site of the tumour and the nipple are less reproducible
but aid the interpretation of the image. The marker images are
then analysed to ﬁnd the pixel with the maximum count rate for
each marker. A direct transform is undertaken if the marker images
for the early and later image ﬁt, otherwise an elastic transform
minimising the differences between the marker images has to be
undertaken. The actual breast and axillary node images are trans-
formed in the same way as their marker images. Errors in
registration may be seen as negative shadows related to blood
vessels, but the movement artefacts can be deceptive. All those
on or above the line of the subclavian arteries and in the neck
are ignored since they are typically due to head and neck move-
ment of the patient between images. As the patients are mainly
from the Breast screening programme and have small tumours,
supraclavicular nodes are most unlikely to be involved. This tech-
nique is not able to detect them because of these movement
artefacts. It is focussed on the need for deﬁning axillary node invol-
vement in relation to axillary clearance.
C
l
i
n
i
c
a
l
Figure 4 Patient W M 18, Tc-99m hHMFG-1 radioimmunoscintigraphy. Positive right axillary nodes and breast cancer.
Table 3 Strategy for the management of the axilla in breast cancer
Palpation and cytology positive; Axillary clearance
Palpation negtive: Imaging axilla
Imaging positive: Axillary clearance
Imaging negative: Sentinel node study
Sentinel node positive on histology: Axillary clearance
Sentinel node negative on histology: No axillary clearance
Axillary node imaging with Tc-99m humanised anti-PEM
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nised hHMFG1 with change detection analysis show good
speciﬁcity: 13 out of 14 true negatives. The one false positive,
patient 20 was due to a second tumour found histologically to
be breast cancer and not due to an involved lymph node. Although
a relatively rare occurrence, a second tumour having the same anti-
gen expression as an involved lymph node, cannot be distinguished
by radioimmunoscintigraphy. The result is a true positive for
cancer cell detection and probably a true positive in management
terms, since if a tumour was known to be in the axilla, an axillary
clearance would be undertaken. The sensitivity 61% however is
disappointing with seven false negative studies in patients 2, 3, 7,
13, 17, 19 and 28. There are several likely explanations. There is
lack of sensitivity of the technique in detecting what were micro-
metastases in patients 2, 3 and 17. The situation in patient 7
(two sentinel nodes and six out of 14 axillary nodes involved), in
patient 19 (seven out of 18 axillary nodes involved) and in patient
28 (11 out of 17 axillary nodes involved) is likely to be due to a
paucity of antigen expression in these tumours’ metastases to the
axillary nodes. In each case the primary tumour was detected.
Patient 7 had a grade 2 invasive lobular carcinoma, patient 19
had a grade 2 mixed ductal and lobular carcinoma and patient
28 had a Grade 3 invasive ductal carcinoma. These are not more
malignant than the average grade of the other true positives. These
results of CDA with Tc-99m hHMFG1 are less good than those of
a previous study from this department (Biassoni et al, 1998) using
CDA with Tc-99m-SM3. SM3 has a higher afﬁnity for breast cancer
than murine HMFG1, whose afﬁnity is similar to the humanised
version of HMFG1. The comparison between this study and the
SM3 study is historical, for the patients were not studied with each
antibody. However the patients were similar in presentation with
the same surgical team attending a similar number of patients.
Unfortunately it has not been possible to humanise SM3 which
reacts with a ﬁve amino acid epitope exposed through the relative
deglycosylation of the cancer cell surface mucin protein as
compared with the normal breast cell or benign breast lesion
(Taylor-Papadimitriou et al, 1981; Burchell et al, 1987, Burchell
and Taylor-Papadimitriou, 1993). This makes it more speciﬁc for
cancer. The advantage of a humanised as compared to a murine
monoclonal antibody is not primarily for imaging where the
HAMA reaction is not a problem until the third or fourth diagnos-
tic imaging is undertaken, but for the requirements of
radioimmunotherapy or inoculation against cancer.
In conclusion the applicability of using a Tc-99m humanised
anti-PEM monoclonal antibody in imaging impalpable axillary
nodes in women with breast cancer has been demonstrated. The
next phase is to return to the use of Tc-99m-SM3, which had a
better sensitivity than hHMFG1, with the more advanced CDA
image analysis technique described and used here.
A strategy for management of axillary clearance is proposed in
Table 3. The imaging technique may be improved radioimmunos-
cintigraphy, improved radiopeptidescintigraphy, improved positron
emission tomography, or improved magnetic resonance imaging.
The combination of negative palpation of the axilla, negative
imaging of the axilla and a negative sentinel node study would
be taken as the criteria to avoid axillary clearance.
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